Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...

A new study finds no significant differences in cardiovascular and thromboembolic risks among biologics for psoriasis or ...

Coherus BioSciences (CHRS) announced final data from its Phase 2 open label clinical trial evaluating casdozokitug, a selective and potent ...

Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...

Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.

Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...